Table 2.
Baseline characteristics of the enrolled patients in the included RCTs.
| Study ID | Study groups | Number of patients | Age, mean (SD) | Sex (male), no. (%) | Race, no. (%) | Disease duration, mean (SD), y | Investigator's global assessment (IGA) grade, no. (%) | Eczema area and severity index (EASI) score, mean (SD) | % body surface area (BSA) affected, mean (SD) | Pruritus numeric rating scale (NRS) score, mean (SD) | Scoring atopic dermatitis (SCORAD), mean (SD) | Pruritus and symptoms assessment for atopic dermatitis (PSAAD), mean (SD) | Patient-oriented eczema measure (POEM), mean (SD) | Dermatology life quality index (DLQI), mean (SD), patients | Children's dermatology life quality index (CDLQI), mean (SD), patients | Previous medications for AD | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | Black | Asian | Others | Not reported | Moderate (grade 3) | Severe (grade 4) | ||||||||||||||||
| Gooderham 2019 | Abrocitinib 10 mg Abrocitinib 30 mg Abrocitinib 100 mg Abrocitinib 200 mg Placebo |
49 51 56 55 56 |
44.3 (15.9) 37.6 (15.9) 41.1 (15.6) 38.7 (17.6) 42.6 (15.1) |
21 (42.9) 22 (43.1) 31 (55.4) 28 (50.9) 21 (37.5) |
38 (77.6) 39 (76.5) 40 (71.4) 37 (67.3) 40 (71.4) |
5 (10.2) 4 (7.8) 7 (12.5) 13 (23.6) 10 (17.9) |
5 (10.2 5 (9.8) ) 8 (14.3) 5 (9.1) 4 (7.1) |
1 (2.0) 3 (5.9) 1 (1.8) 0 (0) 2 (3.6) |
— | 30.3 (14.7) 20.5 (16.35) 23.8 (16.4) 19.6 (16.73) 25.6 (16.5) |
27 (55.1) 28 (56.0) 29 (52.7) 34 (63.0) 34 (61.8) |
22 (44.9) 22 (44.0) 26 (47.3 20 (37.0)) 21 (38.2) |
28.1 (13.1) 22.1 (10.7) 26.7 (11.8) 24.6 (13.5) 25.4 (12.9) |
44.2 (22.7) 34.1 (20.8) 41.9 (22.3) 38.0 (23.3) 40.1 (22.3) |
7.6 (1.7) 7.6 (1.9) 7.4 (2.2) 6.9 (2.7) 7.6 (1.8) |
65.3 (13.2) 62.4 (13.0) 65.4 (13.7) 62.7 (13.7) 65.0 (12.1) |
— | — | — | — | Topical corticosteroids or topical calcineurin inhibitors | |
|
| ||||||||||||||||||||||
| Silverberg 2020 | Abrocitinib 100 mg Abrocitinib 200 mg Placebo |
158 155 78 |
37.4 (15.8) 33.5 (14.7) 33.4 (13.8) |
94 (59.5) 88 (56.8) 47 (60.3) |
101(63.9) 91 (58.7) 40 (51.3) |
9 (5.7) 6 (3.9) 6 (7.7) |
46 (29.1) 54 (34.8) 29 (37.2) |
1 (0.6) 2 (1.3) 1 (1.3) |
1 (0.6) 2 (1.3) 2 (2.6) |
21.1 (14.8) 20.5 (14.8) 21.7 (14.3) |
107 (67.7) 106 (68.4) 52 (66.7) |
51 (32.3) 49 (31.6) 26 (33.3) |
28.4 (11.2) 29.0 (12.4) 28.0 (10.2) |
48.7 (21.4) 47.7 (22.3) 48.2 (20.8) |
7.1 (1.6) 7.0 (1.6) 6.7 (1.9) |
63.8 (11.4) 64.1 (13.1) 64.3 (12.4) |
5.4 (2.1) 5.2 (2.0) 5.1 (2.1) |
20.9 (5.7) 19.7 (5.7) 19.2 (5.5) |
15.4 (7.3), 140 14.8 (6.0), 139 15.0 (7.1), 70 |
13.8 (5.8), 16 12.9 (5.7), 15 10.1 (3.8), 8 |
Anti-inflammatory topical agents alone (226), systemic agents and/or topical agents (162), dupilumab (14) | |
|
| ||||||||||||||||||||||
| Simpson 2020 | Abrocitinib 100 mg Abrocitinib 200 mg Placebo |
156 154 77 |
32·6 (15·4) 33·0 (17·4) 31·5 (14·4) |
90 (58) 81 (53) 49 (64) |
113 (72) 104 (68) 62 (81) |
15 (10) 11 (7) 6 (8) |
26 (17) 26 (17) 6 (8) |
2 (1) 11 (7) 2 (3) |
0 (0) 2 (1%) 1 (1%) |
24·9 (16·1) 22·7 (14·5) 22·5 (14·4) |
92 (59) 91 (59) 46 (60) |
64 (41) 63 (41) 31 (40) |
31·3 (13·6) 30·6 (14·1) 28·7 (12·5) |
50·8 (23·4) 49·9 (24·4) 47·4 (22·7) |
6·9 (2·0) 7·1 (1·9) 7·0 (1·8) |
67·1 (13·7) 64·3 (13·1) 64·5 (13·2) |
5·3 (2·3) 5·4 (2·1) 5·5 (2·0) |
19·5 (6·5) 19·6 (5·9) 19·9 (6·1) |
14·6 (6·5), 121 14·6 (6·8), 119 13·9 (7·3), 60 |
11·7 (6·6), 32 13·2 (5·5), 32 13·6 (7·0), 16 |
Anti-inflammatory topical agents alone (185), systemic agents and/or topical agents (187), dupilumab (30) | |
|
| ||||||||||||||||||||||
| Pfizer (JADE compare trial) 2021 | First 16 weeks | Abrocitinib 100 mg Abrocitinib 200 mg -Placebo Dupilumab 300 mg |
238 226 131 242 |
−(224) 18–65 (14) >=65 −(211) 18–65 (15) >=65 −(121) 18–65 (10) >=65 −(227) 18–65 (15) >=65 |
120 (50.4) 104 (46) 77 (58.8) 108 (44.6) |
182 (76.5) 161 (71.2) 87 (66.4) 176 (72.7) |
6 (2.5) 9 (4) 6 (4.6) 14 (5.8) |
48 (20.2) 53 (23.5) 31 (23.7) 46 (19.0) |
2 (0.0084) 2 (0.0088) 4 (0.031) 4 (0.0165) |
0 (0.0) 1 (0.4) 3 (2.3) 2 (0.8) |
— | — | — | — | — | — | — | — | — | — | — | — |
| Final 4 weeks (16-20) | -Abrocitinib 100 mg (after 16 weeks abrocitinib 100 mg) -Abrocitinib 200 mg (after 16 weeks placebo) Abrocitinib 100 mg (after 16 weeks placebo) Abrocitinib 200 mg (after 16 weeks placebo) Placebo (after 16 weeks dupilumab) |
238 226 60 57 242 |
−(224) 18–65 (14) >=65 −(121) 18–65 (10) >=65 −(121) 18–65 (10) >=65 −(227) 18–65 (15) >=65 |
120(50.4) 104(46) 77 (58.8) 77 (58.8) 108 (44.6) |
182 (76.5) 161 (71.2) 87 (66.4) 87 (66.4) 176(72.7) |
6 (2.5) 9 (4) 6 (4.6) 6 (4.6) 14 (5.8) |
48 (20.2) 53 (23.5) 31 (23.7) 31 (23.7) 46 (19.0) |
2 (0.0084) 2 (0.0088) 4 (0.031) 4 (0.031) 4 (0.0165) |
0 (0.0) 1 (0.4) 3 (2.3) 3 (2.3) 2 (0.8) |
— | — | — | — | — | — | — | — | — | — | — | — | |